主题：Cancer Stem Cell therapy: Progress and Controversies
报告人：Kaladhar B. Reddy, Ph.D.
Department of Pathology Wayne State University School of Medicine
时间：2015年11月17日上午9时
地点：医学楼402栋一楼会议室
欢迎广大师生踊跃参加！
欧洲杯官网
Short Biosketch
Kaladhar B. Reddy, Ph.D.
Office Address: Department of Pathology
Wayne State University School of Medicine 540 E. Canfield, Detroit, MI 48201
Office Phone:(313) 577 - 6191
E-mail Address:kreddy@med.wayne.edu
FACULTY APPOINTMENTS
2015-present Professor, Dept. of Pathology
School of Medicine, Wayne State Univ., Detroit, MI
1998-2015Associate Professor, Dept. of Pathology
School of Medicine, Wayne State Univ., Detroit, MI
2014Member of Tumor Biology and Microenvironment Program (TBM)
Karmanos Cancer Institute (KCI), Detroit, MI
1995- 2009Member, Karmanos Cancer Institute (KCI), Detroit, MI
1993-98Assistant Professor, Dept. of Pathology,
School of Medicine, Wayne State Univ., Detroit, MI
1991-93Member, The Institute for Cancer Research and Care,
San Antonio, TX
1990-93Instructor, Dept. of Medicine/Oncology,
The Univ. of Texas Health Science Center at San Antonio, TX
1985-87Assistant Research Officer,
Indian Council of Medical Research, Madras, India
EDUCATION
1984Ph.D. Biochemistry
Osmania University, Hyderabad, India
1980M.Sc., Biochemistry
Osmania University, Hyderabad, India
1978B.SC., Biological Sciences
Osmania University, Hyderabad, India
Editorial Board Member:
1. ISRN Oncology: Member of International Scholarly Research Network Editorial Board.
2. Scientifica: Member of Oncology Editorial Board.
3. Journal of Cancer Research and Therapy
PUBLICATIONS
1. Ahmad A, Ginnebaugh KR, Yin S, Bollig-Fischer A, Reddy KB and Sarkar FH: Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer (in press). Journal Impact Factor: 3.36
2. Muthu M, Somagoni MS, Cheriyan VT, Munie S, Levi E, Ashour AE, Yassin AEB, Alafeefy AM, Sochacki, Polin LA, Reddy KB, Larsen SD, Singh M, and Rishi AK: Identification and testing of novel CARP-1 functional mimetic compounds as inhibitors of non-small cell lung and triple negative breast cancers. Journal of Biomedical Nanotechnology 11: 1608-1627, 2015. Journal Impact Factor: 7.578.
*3. Reddy KB: MicroRNA (miRNA) in cancer (Review). Cancer Cell International 38: 1-6, 2015.
Journal Impact Factor: 1.991
4. Yin S, Rishi AK and Reddy KB: Anti-estrogen resistant breast cancers cells are sensitive to cisplatin plus TRAIL treatment. Oncology Reports 33: 1475-1480, 2015.
Journal Impact Factor: 2.191
*5. Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar F, Sethi S and Reddy KB: Tumor Initiating Cells and FZD8 play a major role in drug resistance in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 12: 491-498, 2013 [this paper was featured as a highlight by the editors for that issue]. Journal Impact Factor: 6.107
6. Wong C, Wang X, Smith D, Reddy KB, Chen S: AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res. and Treat. 134: 671-81, 2012. Journal Impact Factor: 4.198.
*7. Reddy KB “Triple-Negative Breast Cancers: An updated review on treatment options (Review). Current Oncology 18: 173-179, 2011. (Note: According to current oncology the above article is in top 10 most requested articles for 6 months after publication). Journal Impact Factor: 2.473.
8. Yin S, Xu l, Bandyopadhyay S, Sethi S, and Reddy KB: Cisplatin and TRAIL Enhance Breast Cancer Stem Cell Death. Int. J Oncology 39: 891-898, 2011. Journal Impact Factor: 2.773.
9. Xu L, Yin S, Banerjee S, Sarkar F, and Reddy KB: Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor cells. Molecular Cancer Therapeutics 10: 550-557, 2011. Journal Impact Factor: 6.107
10. Yin S, Sethi S, and Reddy KB: Protein Kinase Cδ and Caspase-3 modulate TRAIL-induced apoptosis in breast tumor cells. Journal of Cellular Biochemistry 111: 979-987, 2010. Journal Impact Factor: 3.368.